Locations:
Search
Study measures real-world outcomes for relapsed or refractory large B-cell lymphoma
Optimized responses in transplant- and CAR T-cell therapy-eligible patients
Findings from large database important to inform clinical practice
Offers a new option for patients 60 and older with relapsed/refractory disease
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
What’s coming up at ASH and beyond
Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone
First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention
Global R&D efforts expanding first-line and relapse therapy options for patients
A case study on the value of access to novel therapies through clinical trials
On-demand stem cell mobilizer is an effective salvage strategy
Advertisement
Advertisement